Zoledronic Acid Restores Doxorubicin Chemosensitivity and Immunogenic Cell Death in Multidrug-Resistant Human Cancer Cells
Open Access
- 12 April 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (4), e60975
- https://doi.org/10.1371/journal.pone.0060975
Abstract
Durable tumor cell eradication by chemotherapy is challenged by the development of multidrug-resistance (MDR) and the failure to induce immunogenic cell death. The aim of this work was to investigate whether MDR and immunogenic cell death share a common biochemical pathway eventually amenable to therapeutic intervention. We found that mevalonate pathway activity, Ras and RhoA protein isoprenylation, Ras- and RhoA-downstream signalling pathway activities, Hypoxia Inducible Factor-1alpha activation were significantly higher in MDR+ compared with MDR− human cancer cells, leading to increased P-glycoprotein expression, and protection from doxorubicin-induced cytotoxicity and immunogenic cell death. Zoledronic acid, a potent aminobisphosphonate targeting the mevalonate pathway, interrupted Ras- and RhoA-dependent downstream signalling pathways, abrogated the Hypoxia Inducible Factor-1alpha-driven P-glycoprotein expression, and restored doxorubicin-induced cytotoxicity and immunogenic cell death in MDR+ cells. Immunogenic cell death recovery was documented by the ability of dendritic cells to phagocytise MDR+ cells treated with zoledronic acid plus doxorubicin, and to recruit anti-tumor cytotoxic CD8+ T lymphocytes. These data indicate that MDR+ cells have an hyper-active mevalonate pathway which is targetable with zoledronic acid to antagonize their ability to withstand chemotherapy-induced cytotoxicity and escape immunogenic cell death.Keywords
This publication has 46 references indexed in Scilit:
- Collateral sensitivity as a strategy against cancer multidrug resistanceDrug Resistance Updates, 2012
- Mutant p53 Disrupts Mammary Tissue Architecture via the Mevalonate PathwayCell, 2012
- Immune parameters affecting the efficacy of chemotherapeutic regimensNature Reviews Clinical Oncology, 2011
- Improved Clinical Outcome in Indolent B-Cell Lymphoma Patients Vaccinated with Autologous Tumor Cells Experiencing Immunogenic DeathCancer Research, 2010
- Dysregulation of the mevalonate pathway promotes transformationProceedings of the National Academy of Sciences of the United States of America, 2010
- The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancerBritish Journal of Cancer, 2010
- Identification of Compounds Selectively Killing Multidrug-Resistant Cancer CellsCancer Research, 2009
- Antitumor Effects of Doxorubicin Followed by Zoledronic Acid in a Mouse Model of Breast CancerJNCI Journal of the National Cancer Institute, 2008
- Immunogenicity of anthracyclines: moving towards more personalized medicineTrends in Molecular Medicine, 2008
- Multidrug resistance in cancer: role of ATP–dependent transportersNature Reviews Cancer, 2002